Author(s):
S. Satya Lakshmi, Y. Srinivasa Rao, D. Asha, P.V. Kamala Kumari, P.N. Mallikarjun
Email(s):
satyalaxmi148@gmail.com
DOI:
10.5958/0974-360X.2020.00841.0 
Address:
S. Satya Lakshmi1*, Y. Srinivasa Rao2, D. Asha3, P.V. Kamala Kumari4, P.N. Mallikarjun5
1Associate Professor, Department of Pharmaceutics, Vignan Institute of Pharmaceutical Technology, Duvvada, Beside VSEZ, Visakhapatnam, Andhra Pradesh, India.
2Professor, Department of Pharmaceutics, Vignan Institute of Pharmaceutical Technology, Duvvada, Beside VSEZ, Visakhapatnam, Andhra Pradesh, India.
3D. Asha, M. Pharm., Department of Pharmaceutics, Vignan Institute of Pharmaceutical Technology, Duvvada, Beside VSEZ, Visakhapatnam, Andhra Pradesh, India.
4P.V. Kamala Kumari, Associate Professor, Department of Pharmaceutics, Vignan Institute of Pharmaceutical Technology, Duvvada, Beside VSEZ, Visakhapatnam, Andhra Pradesh, India.
5P.N. Mallikarjun, Associate Professor, Department of Pharmaceutics, Vignan Institute of Pharmaceutical Technology, Duvvada, Beside VSEZ, Visakhapatnam, Andhra Pradesh, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 10,
Year - 2020
ABSTRACT:
Rosuvastatin calcium is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. Like remaining statins Rosuvastatin-calcium is also a poorly soluble drug and not exceeding 20% of bioavailability due to first pass metabolism. To overcome these drawbacks the present study aimed to formulate transdermal patch of Rosuvastatin calcium. Totally seven patches were developed by incorporating HPMC and PVP using solvent casting method. The formulations were evaluated for hardness, compatibility studies, solubility, weight variation, thickness, physical appearance, tensile strength, % drug content, % moisture content, % moisture uptake and in vitro drug release. The evaluated parameters were within the limit only. FTIR spectroscopy revealed that the drug, polymers and other excipients were compatible with each other. When compared to other formulations T1 formulation exhibited better in vitro drug release profile across the cellulose membrane. The skin irritation studies using rabbits revealed no signs of irritation or oedema, which confirms that the drug loaded and plain patches were compatible with skin. The trandermal patch loaded with Rosuvastatin-calcium used conveniently as an antilipemic agent.
Cite this article:
S. Satya Lakshmi, Y. Srinivasa Rao, D. Asha, P.V. Kamala Kumari, P.N. Mallikarjun. Formulation and Evaluation of Rosuvastatin-Calcium Drug Transdermal Patch. Research J. Pharm. and Tech. 2020; 13(10):4784-4790. doi: 10.5958/0974-360X.2020.00841.0
Cite(Electronic):
S. Satya Lakshmi, Y. Srinivasa Rao, D. Asha, P.V. Kamala Kumari, P.N. Mallikarjun. Formulation and Evaluation of Rosuvastatin-Calcium Drug Transdermal Patch. Research J. Pharm. and Tech. 2020; 13(10):4784-4790. doi: 10.5958/0974-360X.2020.00841.0 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-10-44
REFERENCES:
1. Sidney S, Quesenberry CP, Jaffe MG. Recent trends in cardiovascular mortality in the United States and public health goals. Journal of American college of Cardiology. 2016; 1(5):594-599.
2. Kim J, Kitakaze M. Prevention and treatment of the hypersensitive organopathy - the necessity of cardiovascular protection. Nippon Rinsho. 2004; 62(1):120-127.
3. Amish VP, Markand Mehta, Viral HS, Umesh Upadhyay. Formulation and invitro evaluation of mucoadhesive bilayered buccal tablets of rosuvastatin calcium. International Journal of Pharmaceutical Sciences and Research. 2012; 3(8):2733-2740.
4. Omar SS, Laith HS, Wedad K. Formulation and invitro evaluation of rosuvastatin calcium Niosomes. International Journal of Pharmacy and Pharmaceutical Sciences. 2013, 5(4): 525-535.
5. Gaur PK, Mishra S, Purohit S, Dave K. Transdermal drug delivery system: A review. Asian Journal of Pharmaceutical and Clinical Research. 2009; 2(1):14-20.
6. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive: a randomized controlled trial. Journal of American Medical Association. 2001; 285(18):2347- 2354.
7. Ghulaxe C, Verma R. A review on transdermal drug delivery system. The Pharma Innovation Journal. 2015; 4(1):37-43.
8. Shingade GM, Quazi A, Sabale PM, Grampurohit ND, Gadhave MV, Jadhav SL. Review on: Recent trend on transdermal drug delivery system. Journal of Drug Delivery and Therapeutics. 2012; 2(1):66-75.
9. Shabbir M, Sajid A, Nabeel S, Rehman K, Amin U, Moosa R. Formulation considerations and factors affecting transdermal drug delivery system-A review. International Journal of Pharmacy and Integrated Life Sciences. 2014; 2(9):20-35.
10. Shivraj A, Pannerselvam R, Tamizmani T, Sivakumar T. Design and evaluation of transdermal drug delivery of ketotifen fumarate. International Journal of Pharmaceutical and Biomedical Research. 2010; 1(2):42-47.
11. Chakshu Bhatia, Monika Sachdeva, Meenakshi Bajpai. Formulation and evaluation of transdermal patch of pregabalin. International Journal of Pharmaceutical Sciences and Research. 2012; 3(2):569-575.
12. Subramanian S, Keerthana Devi M, Vaiyana Rajesh C, Sakthi M, Suganya G, Ravichandran S. Preparation, evaluation and optimization of Atorvastatin nanosuspension incorporated transdermal patch. Asian Journal of Pharmaceutics. 2016; 10(4):487-491.
13. Geeta A, Manisha P, Harikumar S. Formulation and evaluation of transdermal drug delivery system of Simvastatin using natural and synthetic permeation enhancer. Der Pharmacia Lettre. 2014; 6(1):358-368.